earli
transfus
compat
hemolysi
whether
delay
immedi
lifethreaten
conditionrisk
blood
group
discov
avoid
stimul
alloantibodi
becam
norm
transfus
transmiss
infect
becam
greater
risk
risk
acut
hemolyt
transfus
reaction
report
bacteri
contamin
platelet
infect
usual
immedi
evid
came
recogn
equal
fatal
immedi
death
septic
transfus
test
syphili
initi
syphili
diseas
direct
transfus
causal
organ
stabl
colder
temperatur
h
viabl
becom
nonviabl
immedi
freez
temperatur
blood
longer
collect
paid
donor
inmat
decreas
incid
transmiss
hepat
develop
health
questionnair
eventu
becam
univers
health
questionnair
risk
transmiss
began
declin
test
develop
detect
antibodi
eventu
antigen
hepat
virus
decreas
risk
transfus
transmiss
eventu
nucleic
acid
test
nat
develop
detect
exposur
pathogen
detect
genet
materi
donor
result
lower
risk
transmiss
infect
creat
safest
blood
product
histori
infect
rate
virus
low
secondari
screen
higher
incid
rate
measur
directli
rate
less
mathemat
model
requir
predict
residu
risk
testament
benefit
screen
questionnair
serolog
test
nat
produc
safest
transfus
blood
compon
date
chapter
explor
virus
bacteria
parasit
briefli
prion
specif
exampl
mode
detect
risk
risk
mitig
final
may
done
futur
reduc
current
potenti
risksdang
pathogen
discuss
even
though
agent
transmiss
hepat
known
virus
risk
transfus
transmiss
hepat
recogn
sinc
regul
place
sinc
decreas
risk
transmiss
hepat
long
caus
agent
identifi
individu
hepat
screen
via
health
donor
questionnair
except
hepat
age
approxim
donor
defer
base
sole
questionnair
awar
ill
screen
enzymat
immunoassay
test
detect
presenc
hepat
b
surfac
antigen
hepat
b
surfac
antibodi
hepat
b
core
antibodi
alanin
transferas
use
nat
sinc
histor
hepat
caus
hepat
b
virus
call
hepat
nona
nonb
major
found
hepat
c
screen
hepat
b
posttransfus
hepat
risk
due
hepat
c
like
hepat
b
viru
virus
caus
hepat
c
typic
indol
cours
may
lead
sever
morbid
eventu
mortal
liver
failur
hepat
carcinoma
virus
detect
donor
enzymat
immunoassay
eia
test
recombin
immunoblot
assay
confirm
nat
transmiss
infect
decreas
virus
routin
screen
human
tlymphotroph
viru
htlv
human
immunodefici
viru
hiv
htlv
two
copi
singlestrand
rna
ssrna
discov
htlv
caus
lymphoprolif
demyelin
diseas
infect
lead
tcell
leukemia
htlvassoci
myelopathi
prevent
transmiss
viru
serolog
test
antibodi
htlv
perform
sinc
eia
sensit
specif
western
blot
sensit
specif
respect
receiv
seroposit
blood
product
convers
rate
product
store
longer
less
like
infecti
store
less
day
contamin
unit
transmiss
rate
store
longer
day
risk
decreas
multipl
case
report
around
world
demonstr
transfus
transmiss
viru
one
case
walk
donor
pool
acquir
treatment
militari
combat
oper
present
nat
perform
htlv
none
develop
preval
infect
worldwid
low
preval
unit
state
posit
result
firsttim
test
donor
screen
chanc
transmiss
infect
hiv
stori
histori
blood
commun
hiv
positivesens
ssrna
envelop
viru
initi
infect
transmiss
via
blood
transfus
thought
rare
event
time
progress
serious
acquir
immunodefici
syndrom
prognosi
eas
transmiss
via
blood
transfus
becam
appreci
health
questionnair
screen
develop
highrisk
popul
identifi
earli
transfus
transmiss
hiv
recogn
work
screen
test
came
forefront
screen
histori
high
risk
suffici
protect
transfus
recipi
earli
serolog
test
hiv
develop
donor
test
initi
questionnair
decreas
risk
screen
eia
antigen
test
western
blot
confirm
decreas
risk
final
nat
decreas
risk
four
case
transfus
transmiss
report
unit
state
last
case
transmiss
hiv
via
blood
transfus
occur
continu
format
new
clade
requir
updat
questionnair
test
done
recent
clade
recent
arriv
one
africa
phase
iii
present
wnv
associ
potenti
fatal
neurolog
diseas
meningoenceph
flaviviru
ssrna
viru
natur
reservoir
bird
transmit
incident
host
human
hors
mammal
via
mosquito
first
seen
new
york
transfus
transmit
case
note
unit
state
symptom
mild
sever
meningoenceph
infect
asymptomat
develop
nat
viru
rapid
ind
research
test
went
smoothli
perman
test
put
place
risk
viral
transmiss
zika
infect
newli
document
transfus
transmiss
infect
zika
viru
positivesens
ssrna
envelop
viru
first
evid
africa
time
spread
africa
asia
found
caus
microcephali
vivoinfect
fetus
mother
infect
viru
brazil
least
countri
world
activ
zika
infect
zika
viremia
may
last
week
primari
infect
sinc
nov
nat
phase
iii
test
unit
state
food
drug
administr
fda
approv
licens
screen
test
pend
previou
nat
risk
transmiss
decreas
risk
transfus
transmiss
seen
hepat
c
viru
hiv
test
cmv
doublestrand
dna
dsdna
envelop
viru
also
call
human
human
sole
host
viru
transmit
persontoperson
contact
iatrogen
via
blood
transfus
tissueorgan
transplant
primari
infect
lifelong
viral
persist
like
within
mononuclear
white
cell
hematopoiet
progenitor
cell
bone
marrow
cmv
infect
pregnanc
affect
neurodevelop
fetu
vertic
transmiss
rate
immunocompromis
patient
receiv
bone
marrowstem
cell
transplant
infect
caus
sever
diseas
pulmonari
gastrointestin
central
nervou
system
immunocompet
individu
typic
mild
flulik
symptom
primari
infect
viru
remain
white
cell
repeat
infect
also
seen
seroneg
prestorag
leukocytereduc
blood
product
decreas
risk
cmv
transmiss
may
addit
benefit
leukodeplet
neg
serolog
togeth
recent
studi
conclud
cmvseroneg
blood
product
safer
leukoreduc
blood
product
debat
continu
residu
risk
leukocyt
reduct
cmv
transfus
transmiss
virus
caus
viremia
potenti
transfus
transmiss
screen
histori
test
blood
donor
set
virus
may
geograph
isol
produc
mild
clinic
symptom
yet
identifi
transfus
transmiss
case
ebv
dsdna
envelop
viru
human
reservoir
blood
transfus
transmiss
report
rare
primari
infect
lead
mononucleosi
burkitt
lymphoma
nasopharyng
carcinoma
postvir
lymphoprolifer
primari
infect
viru
remain
latent
lymphocyt
infect
preval
age
year
screen
time
donat
defer
hepat
age
serolog
test
nat
avail
parvoviru
b
positiveor
negativesens
singlestrand
dna
nonenvelop
viru
viru
resist
pathogen
reduct
techniqu
heat
cold
treatment
solvent
deterg
treatment
viru
discov
three
genotyp
parvoviru
b
trophic
red
cell
demonstr
high
viremia
rate
day
postinfect
preval
previou
infect
adulthood
associ
transfusionassoci
transmiss
infect
lead
fifth
diseas
children
fetal
hydrop
unborn
patient
high
red
cell
turnov
rate
suscept
aplast
anemia
follow
infect
viru
current
screen
test
blood
donor
center
nat
perform
pool
blood
compon
product
produc
commerci
albumin
intraven
immunoglobulin
ivig
antid
immun
globulin
etc
chikungunya
ssrna
envelop
viru
two
genotyp
vector
viru
multipl
mosquito
speci
bird
human
mammal
reptil
reservoir
viru
high
concentr
viremia
occur
within
first
week
infect
atrisk
popul
sever
diseas
includ
elderli
pregnant
immunocompromis
patient
present
theoret
risk
associ
transfus
transmiss
present
screen
test
avail
dengu
viru
posit
ssrna
envelop
viru
four
serotyp
least
two
mosquito
vector
viru
human
main
host
viremia
may
present
day
postinfect
infect
lead
dengu
sever
dengu
fever
also
known
dengu
hemorrhag
fever
incid
infect
increas
last
year
viru
mainli
present
tropic
subtrop
asia
america
associ
transfus
transmiss
seen
cellular
acellular
blood
compon
transmiss
also
seen
needl
stick
organ
transplant
dengu
vaccin
develop
individu
age
year
endem
area
blood
screen
test
develop
use
part
world
emerg
viral
infect
transmiss
via
transfus
includ
limit
human
poxviru
monkeypox
viru
whitewat
arroyo
viru
hantaviru
caus
hantaviru
pulmonari
syndrom
virus
caus
yellow
fever
marburg
hemorrhag
fever
ebola
hemorrhag
fever
enteroviru
hendra
viru
nipah
viru
avian
influenza
viru
virus
caus
sever
acut
respiratori
syndrom
lassa
fever
rift
valley
fever
hepatitisg
viru
gbvc
ttv
sen
viru
risk
transmiss
infect
remain
rel
low
season
donor
health
questionnair
dhq
healthi
today
travel
histori
temperatur
measur
ensur
approxim
potenti
infecti
donor
screen
futur
pathogen
reduct
technolog
protect
infecti
agent
histor
risk
transfus
transmiss
bacteria
underappreci
gain
control
screen
virus
potenti
clinic
sequela
bacteremicsept
transfus
reaction
receiv
attent
transmiss
organ
much
frequent
virus
dhq
miniphys
examin
punctur
site
prepar
divers
pouch
subcultur
platelet
unit
decreas
risk
somewhat
septic
reaction
occur
bacterialpathogencontamin
blood
compon
usual
origin
blood
donor
venipunctur
site
unsuspect
bacteremia
less
commonli
may
also
result
donor
unit
process
bacteri
contamin
like
occur
compon
store
room
temperatur
compon
store
refriger
risk
transfus
transmiss
remain
rel
high
red
cell
platelet
oppos
residu
risk
viral
screen
time
collect
bacteri
contamin
compon
coloni
form
unit
cfu
ml
initi
sepsi
occur
compon
store
short
period
end
storag
time
howev
compon
cfuml
level
contamin
much
easili
lead
sepsi
especi
atrisk
immunocompromis
patient
staphylococcu
pseudomona
optim
condit
doubl
everi
h
without
lag
phase
even
cold
storag
bacteremiasepsi
associ
transfus
compon
red
cell
compon
store
longer
day
implic
bacterem
transfus
often
still
red
blood
cell
compon
store
longer
day
yersinia
enterocolitica
pseudomona
fluorescen
common
agent
associ
bacterem
transfus
reaction
involv
red
blood
cell
compon
enterocolitica
lag
time
doubl
time
remaind
storag
period
contamin
level
reach
cfuml
day
storag
prestorag
leukoreduct
may
prevent
inhibit
yersinia
prolifer
red
cell
store
short
time
continu
associ
treponema
pallidum
transmiss
less
common
red
cell
compon
bacteri
contamin
pseudomona
sp
flavobacterium
sp
campylobact
jejuni
enterobact
sp
klebsiella
sp
escherichia
coli
serratia
sp
proteu
sp
staphylococcu
aureu
coagulaseneg
staphylococcu
sinc
bacteri
contamin
platelet
compon
recogn
bacteria
lead
caus
death
transfus
transmit
infect
singledonor
platelet
apheresi
platelet
concentr
donor
pool
store
higher
temperatur
red
cell
unit
platelet
store
agit
day
storag
condit
favor
aerob
bacteri
growth
organ
typic
caus
bacteri
septicemia
often
skin
flora
includ
staphylococcu
streptococcu
howev
serratia
bacillu
salmonella
also
among
common
bacteri
contamin
platelet
product
acinetobact
proteu
klebsiella
serratia
also
implic
fatal
septic
transfus
reaction
propionibacterium
acn
found
common
contamin
blood
product
usual
associ
minim
morbid
mortal
nonetheless
one
fatal
reaction
transfus
report
bacteremicsept
reaction
usual
seen
end
storag
platelet
unit
day
higher
bacteri
septic
reaction
secondari
longer
store
platelet
unit
led
fda
revers
storag
day
period
storag
attempt
subcultur
platelet
h
collect
tri
screen
contamin
unit
reduc
risk
slightli
significantli
storag
set
day
storag
limit
day
longer
storag
continu
associ
unaccept
rate
bacteri
transmiss
aureu
contamin
platelet
lag
wherea
enterococcu
faecali
lag
growth
period
doubl
time
organ
h
day
cfuml
compon
efficaci
remov
bacteria
leukocyt
deplet
less
clear
platelet
product
risk
bacteremia
platelet
transfus
transfusionrel
sepsi
risk
rang
depend
studi
subcultur
risk
immedi
death
septic
transfus
potenti
sourc
contamin
blood
product
improp
prepar
phlebotomi
site
donat
donor
bacteremia
blood
contain
use
process
storag
equip
use
process
risk
transmiss
donor
decreas
miniphys
examin
clinic
medic
travel
histori
phlebotomi
site
risk
reduc
rule
intraven
drug
use
evalu
skin
lesion
prepar
site
iodin
chlorhexidin
alcohol
donor
bacteremia
risk
evalu
histori
dental
procedur
gastrointestin
tract
symptom
current
osteomyel
contamin
blood
collect
contain
rare
event
better
steril
plastic
use
process
thaw
product
water
bath
may
sourc
contamin
clean
regularli
time
issu
step
taken
visual
inspect
unit
color
chang
hemolysi
turbid
perform
red
cell
unit
tend
much
darker
color
bacteria
use
oxygen
store
red
cell
platelet
lower
ph
loos
swirl
potenti
contamin
present
unit
quarantin
issu
patient
blood
compon
transfus
within
h
issu
blood
bank
proper
storag
temperatur
transport
also
recommend
transfus
administr
tube
set
chang
blood
transfus
per
polici
approxim
everi
h
time
issu
product
examin
evalu
contamin
septic
reaction
fourth
lead
caus
death
complic
transfus
receiv
transfus
sign
septic
reaction
includ
temperatur
greater
f
higher
c
baselin
temperatur
chill
rigor
tachycardia
heart
rate
greater
beat
baselin
shockfal
systol
blood
pressur
mm
hg
systol
backach
nauseavomit
unexplain
bleed
mucou
membran
infus
site
renal
failur
may
follow
later
suspect
transfus
immedi
halt
patient
given
support
treatment
maintain
respiratori
statu
use
mechan
ventil
indic
maintain
cardiovascular
support
vasopressor
indic
patient
stabil
initi
transfus
reaction
workup
send
blood
pink
purpl
tube
first
posttransfus
urin
foley
collect
bag
laboratori
also
send
unit
attach
administr
set
laboratori
perform
gram
stain
cultur
implic
blood
compon
administr
set
draw
blood
cultur
patient
prefer
two
site
prompt
initi
intraven
antibiot
indic
gram
stain
result
futur
use
pathogen
reduct
agent
greatli
decreas
risk
bacteri
transmiss
blood
product
parasit
leishmania
speci
intracellular
macrophag
monocyt
protozoan
caus
leishmaniasi
sandfli
vector
pathogen
case
transmiss
blood
product
report
unit
state
like
leukocyt
reduct
greatli
reduc
transfus
transmiss
pathogen
within
white
blood
cell
protozoan
abl
surviv
day
erythrocyt
storag
condit
deferr
potenti
donor
travel
histori
countri
endem
pathogen
like
aid
prevent
transmiss
unit
state
travel
histori
deferr
incub
infect
may
week
month
pathogen
reduct
technolog
decreas
viabil
factor
plasmodium
speci
intracellular
erythrocyt
protozoan
pathogen
spend
part
life
cycl
hepatocyt
malaria
common
diseas
worldwid
caus
pathogen
anophel
mosquito
vector
plasmodium
univers
health
donor
questionnair
extens
travel
histori
question
exposureprophylaxi
use
includ
decreas
risk
deferr
travel
endem
area
deferr
live
endem
area
deferr
year
malaria
asymptomat
center
diseas
control
prevent
frequent
updat
travel
exposur
risk
use
blood
donor
center
ensur
decreas
risk
exposur
fdaapprov
screen
test
malaria
histor
protozoan
surviv
day
blood
contain
new
studi
effect
modern
addit
solut
surviv
organ
leukocyt
reduct
unlik
decreas
risk
transmiss
ongo
pathogen
reduct
studi
promis
reduc
transmiss
via
blood
transfus
endem
region
babesia
intracellular
erythrocyt
protozoa
caus
babesiosi
associ
transfus
transmiss
shown
least
transfus
event
red
cell
compon
freez
red
cell
prevent
transmiss
infect
organ
close
relat
plasmodium
vector
babesia
ixodid
tick
primari
speci
unit
state
babesia
microti
commonli
seen
unit
state
new
england
region
north
midwest
state
eg
wisconsin
minnesota
human
accident
host
risk
transmiss
patient
infect
organ
long
incub
period
week
tick
bite
week
contamin
transfus
well
prolong
infect
mani
asymptomat
mild
fever
immunocompromis
patient
may
develop
hemolysi
dissemin
intravascular
coagul
multipl
organ
dysfunct
syndrom
travel
histori
remot
incid
inocul
poor
screen
tool
present
serolog
polymeras
chain
reaction
studi
perform
immunofluoresc
assay
ifa
enzymelink
immunosorb
assay
elisa
nat
phase
iii
clinic
trial
ongo
test
pathogen
screen
potenti
infect
donor
prion
infect
agent
classic
sens
protein
act
infecti
particl
recruit
normal
cellular
isoform
form
diseasecaus
isoform
creutzfeldtjakob
diseas
cjd
may
sporad
infecti
inherit
even
though
potenti
transfus
transmiss
diseas
date
document
human
case
transfus
transmiss
classic
form
cjd
donor
test
deferr
perman
histori
ill
variant
cjd
stori
differ
diseas
first
occur
unit
kingdom
recogn
distinct
diseas
bovin
spongiform
encephalopathi
mad
cow
diseas
known
vector
cattl
human
serv
reservoir
experiment
anim
intravascular
phase
present
symptom
widespread
deposit
replic
lymphoreticular
tissu
transfus
transmiss
document
prion
like
surviv
storag
condit
blood
product
secondari
physiochem
characterist
note
prion
incub
infect
year
transfus
incub
quicker
year
leukocyt
reduct
may
offer
protect
nanofiltr
effect
experiment
model
system
affinitybas
prion
remov
filter
develop
pathogen
reduct
unknown
effect
prion
past
rate
transfus
transmiss
infect
transfus
better
screen
question
travelmed
histori
screen
test
decreas
risk
transfus
transmiss
infect
manyfold
lower
level
primari
caus
death
infect
transfus
transfus
transmit
infect
may
caus
transfusionassoci
death
fig
becom
good
discov
transfus
transmit
agent
screen
presenc
fig
howev
take
time
new
virul
pathogen
may
still
await
us
protect
geographi
pathogen
reduct
technolog
soon
becom
routin
unit
state
europ
technolog
becom
easier
use
becom
accept
util
first
highrisk
immunocompromis
popul
univers
happen
leukocyt
reduct
commerci
develop
test
perform
screen
pathogen
nanofiltr
solvent
deterg
pasteur
reduc
risk
pathogen
transmiss
detect
screen
test
process
use
cellular
product
process
place
pathogen
reduct
platelet
plasma
whole
blood
red
cell
compon
phase
iii
studi
ongo
near
futur
ad
pathogen
reduct
repertoir
research
project
terumo
